CMPS COMPASS Pathways Plc - American Depository Shares
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 5, 2026
$11.90
· % 处于52周区间
· 高于低点
· 至高点
$4.8852周低点
$15.8752周高点
市值 (MRQ)
$1.62B
P/E
-3.9
EPS
$-3.08
CMPS 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$11.90
市值 (MRQ)
$1.62B
P/E
-3.9
EPS
$-3.08
ROE
-524.8%
负债/权益 (MRQ)
0.6
52周区间
$5–$16
CMPS 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
关于 COMPASS Pathways Plc - American Depository Shares 公司概况（来自维基百科）
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder (PTSD) New Drug Application (NDA), Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wallach's lab is said to have sought patents for over 200 novel compounds as of May 2024.
Compass Pathways switched from being a nonprofit organization to a for-profit company in 2016. The pharmaceutical company has been backed and funded by a number of tech entrepreneurs such as Peter Thiel. The media outlet Sifted remarks that the biotech billionaire Christian Angermayer was instrumental in the founding of Compass Pathways."
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Healthcare
行业Biotechnology
员工156
国家GB
10年表现 收入、净利润、利润率和每股收益趋势
EPS$-3.082019-12-31 → 2025-12-31
自由现金流·2021-12-31 → 2024-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | CMPS | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E | -3.95年均值 ≈-4.7 | ≈-4.7 | · | · | |
| 市净率 (MRQ) | 19.1 | · | 6.8 | 估值过高 | |
| EV / EBITDA (企业价值 / EBITDA) | -5.7 | · | · | · | |
| Price / Cash Flow (市现率) | -7.3 | · | · | · | |
| Price / Tangible Book (市净率（有形资产）) | 2.9 | · | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | CMPS | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| ROA | -135.8%5年均值 ≈-62.9% | ≈-62.9% | -5.4% | 弱 | |
| ROE | -524.8%5年均值 ≈-147.3% | ≈-147.3% | -9.2% | 弱 | |
| ROIC | 836.7%5年均值 ≈117.6% | ≈117.6% | -17.1% | 顶尖 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | CMPS | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | 0.6 | · | · | · | |
| 流动比率 (MRQ) | 1.35年均值 ≈10.4 | ≈10.4 | 4.5 | 低流动性 | |
| Quick Ratio (速动比率) | 0.65年均值 ≈8.8 | ≈8.8 | 3.2 | 低流动性 | |
| 长期负债/股东权益 (MRQ) | 0.6 | · | · | · |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
此比率组尚无数据
基本面数据不足，尚无法计算此比率组。
资本效率 资产周转率、库存周转率、应收账款周转率
此比率组尚无数据
基本面数据不足，尚无法计算此比率组。
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-103.4%
下次报告
十一月 02, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 七月 29, 2026 | $-1.88 | $-0.41 | -364.1% |
| 2026年3月31日 | 五月 13, 2026 | $-0.30 | $-0.39 | 22.2% |
| 2025年12月31日 | $-1.00 | $-0.40 | -148.6% | |
| 2025年9月30日 | $-1.44 | $-0.40 | -262.0% | |
| 2025年6月30日 | $-0.41 | $-0.44 | 6.1% | |
| 2025年3月31日 | $-0.38 | $-0.48 | 20.4% | |
| 2024年12月31日 | $-0.63 | $-0.64 | 2.3% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $118M | $119M | $88M | $65M | $44M | $23M | |
| SG&A Expense | $61M | $59M | $49M | $45M | $39M | $28M | |
| Operating Expenses | $179M | $178M | $137M | $110M | $83M | $51M | |
| Operating Income | $-179M | $-178M | $-137M | $-110M | $-83M | $-51M | |
| Interest Expense | · | · | $2M | $0 | $0 | · | |
| Interest Income | $7M | $8M | $5M | · | · | · | |
| Other Non-op | $1M | $823.0K | $255.0K | $19M | $12M | $-9M | |
| Pretax Income | $-290M | $-154M | $-118M | $-91M | $-72M | $-60M | |
| Income Tax | $-2M | $2M | $780.0K | $408.0K | $199.0K | $32.0K | |
| Net Income | $-288M | $-155M | $-118M | $-92M | $-72M | $-60M | |
| EPS (Basic) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 | $-3.55 | |
| EPS (Diluted) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 | $-3.55 | |
| Shares (Basic) | 93,504,836 | 67,482,902 | 51,028,024 | 42,436,292 | 39,997,587 | 16,991,664 | |
| Shares (Diluted) | 93,504,836 | 67,482,902 | 51,028,024 | 42,436,292 | 39,997,587 | 16,991,664 | |
| EBITDA | $-179M | $-178M | $-137M | $-110M | $-83M | · |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $150M | $165M | $220M | $143M | $273M | $190M | |
| Prepaid Expense | $42M | $36M | $41M | $48M | $22M | $12M | |
| Other Current Assets | $6M | $4M | $2M | $1M | $1M | $509.0K | |
| Current Assets | $191M | $201M | $261M | $192M | $295M | $202M | |
| PP&E (Net) | · | $189.0K | $423.0K | $617.0K | $398.0K | $245.0K | |
| PP&E (Gross) | · | · | · | $1M | $756.0K | $433.0K | |
| Accum. Depreciation | · | · | · | $530.0K | $358.0K | $188.0K | |
| Other Non-current Assets | $12M | $7M | $7M | $1M | $213.0K | $57.0K | |
| Total Assets | $210M | $214M | $276M | $197M | $301M | $203M | |
| Accounts Payable | $15M | $12M | $6M | $5M | $3M | $3M | |
| Current Liabilities | $248M | $34M | $20M | $16M | $15M | $7M | |
| Capital Leases | $1M | $303.0K | $2M | $418.0K | $1M | · | |
| Total Liabilities | $263M | $59M | $50M | $16M | $16M | $7M | |
| Long-term Debt | $32M | $30M | $29M | $0 | · | · | |
| Total Debt | $32M | $30M | · | · | · | · | |
| Common Stock | $973.0K | $702.0K | $635.0K | · | · | · | |
| Paid-in Capital | $784M | $705M | $622M | $459M | $445M | $279M | |
| Retained Earnings | $-823M | $-535M | $-380M | $-261M | $-170M | $-98M | |
| AOCI | $-15M | $-16M | $-17M | $-17M | $9M | $15M | |
| Stockholders' Equity | $-53M | $155M | $226M | $181M | $284M | $197M | |
| Liabilities + Equity | $210M | $214M | $276M | $197M | $301M | $203M | |
| Shares Outstanding | 96,085,785 | 68,552,215 | 61,943,471 | · | · | · |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | · | · | $242.0K | $330.0K | $175.0K | $112.0K | |
| Stock-based Comp | $14M | $20M | $17M | $13M | $9M | $18M | |
| Deferred Tax | $22.0K | $-437.0K | $-1M | $-1M | $-545.0K | $-221.0K | |
| Other Non-cash | · | · | $5M | $-26M | $-4M | · | |
| Operating Cash Flow | $-157M | $-119M | $-97M | $-105M | $-68M | $-41M | |
| CapEx | · | $0 | $66.0K | $596.0K | $334.0K | $131.0K | |
| Investing Cash Flow | · | $0 | $-64.0K | $-596.0K | $-334.0K | $-628.0K | |
| Debt Issued | · | $0 | $30M | $0 | $0 | · | |
| Net Debt Issued | · | $0 | $30M | · | · | · | |
| Stock Issued | $140M | $26M | $145M | $440.0K | $155M | $0 | |
| Net Stock Activity | $140M | $26M | $145M | $440.0K | $155M | · | |
| Financing Cash Flow | $141M | $64M | $174M | $1M | $157M | $194M | |
| Net Change in Cash | $-15M | $-55M | $77M | $-130M | $83M | $165M | |
| Taxes Paid | $755.0K | · | · | · | · | · | |
| Free Cash Flow | · | $-119M | $-97M | $-106M | $-68M | · | |
| Levered FCF | · | · | $-100M | · | · | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| ROA | -135.8% | -63.4% | -50.1% | -36.7% | -28.4% | · | |
| ROE | -524.8% | -89.2% | -49.5% | -48.7% | -24.3% | · | |
| ROIC | 836.7% | -97.4% | -61.1% | -61.2% | -29.3% | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.8 | 5.9 | 13.3 | 12.3 | 19.5 | · | |
| Quick Ratio | 0.6 | 4.9 | 11.2 | 9.2 | 18.1 | · | |
| Debt / Equity | -0.6 | 0.2 | · | · | · | · | |
| LT Debt / Equity | -0.3 | 0.2 | · | · | · | · | |
| Interest Coverage | · | · | -62.1 | · | · | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.55 | $2.26 | · | · | · | · | |
| Cash Flow / Share | $-1.68 | $-1.77 | $-1.91 | $-2.48 | $-1.69 | · | |
| Cash / Share | $1.56 | $2.41 | · | · | · | · | |
| EPS (TTM) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-288M | $-155M | $-118M | $-92M | $-72M | · | |
| Market Cap | $663M | $259M | · | · | · | · | |
| Enterprise Value | $545M | $124M | · | · | · | · | |
| P/E | -2.2 | -1.6 | -3.8 | -3.7 | -12.3 | · | |
| P/B | -12.5 | 1.7 | · | · | · | · | |
| P / Tangible Book | · | 1.7 | · | · | · | · | |
| P / Cash Flow | -4.2 | -2.2 | · | · | · | · | |
| P / FCF | · | -2.2 | · | · | · | · | |
| EV / EBITDA | -3.0 | -0.7 | · | · | · | · | |
| EV / FCF | · | -1.0 | · | · | · | · | |
| Earnings Yield | -44.6% | -60.9% | -26.5% | -26.9% | -8.1% | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $29M | $26M | $30M | $27M | $30M | $31M | $32M | $33M | $29M | $25M | $27M | $22M | $20M | $19M | $20M | $14M | |
| SG&A Expense | $23M | $16M | $16M | $13M | $13M | $19M | $16M | $15M | $14M | $14M | $11M | $13M | $13M | $13M | $12M | $12M | |
| Operating Expenses | $52M | $43M | $46M | $41M | $43M | $50M | $48M | $48M | $43M | $39M | $38M | $34M | $33M | $32M | $32M | $26M | |
| Operating Income | $-52M | $-43M | $-46M | $-41M | $-43M | $-50M | $-48M | $-48M | $-43M | $-39M | $-38M | $-34M | $-33M | $-32M | $-32M | $-26M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | $1M | · | $0 | $0 | $0 | |
| Interest Income | $4M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $638.0K | · | · | · | |
| Other Non-op | $546.0K | $484.0K | $370.0K | $383.0K | $-176.0K | $803.0K | $337.0K | $191.0K | $167.0K | $128.0K | $-8M | $112.0K | $-11.0K | $8M | $1M | $7M | |
| Pretax Income | $-253M | $91M | $-97M | $-138M | $-38M | $-18M | $-42M | $-38M | $-38M | $-35M | $-32M | $-33M | $-28M | $-24M | $-31M | $-18M | |
| Income Tax | $331.0K | $-11.0K | $-3M | $-230.0K | $137.0K | $354.0K | $1M | $173.0K | $176.0K | $222.0K | $394.0K | $62.0K | $194.0K | $130.0K | $92.0K | $120.0K | |
| Net Income | $-254M | $91M | $-94M | $-138M | $-38M | $-18M | $-43M | $-39M | $-38M | $-35M | $-33M | $-33M | $-28M | $-24M | $-31M | $-18M | |
| EPS (Basic) | $-1.88 | $0.71 | $-1.03 | $-1.44 | $-0.41 | $-0.20 | $-0.63 | $-0.56 | $-0.56 | $-0.55 | $618.92 | $-0.67 | $-620.00 | $-0.57 | $-0.73 | $-0.43 | |
| EPS (Diluted) | $-1.88 | $-0.30 | $-0.99 | $-1.44 | $-0.41 | $-0.24 | $-0.63 | $-0.56 | $-0.56 | $-0.55 | $618.92 | $-0.67 | $-620.00 | $-0.57 | $-0.73 | $-0.43 | |
| Shares (Basic) | 135,039,810 | 110,064,581 | · | 95,337,993 | 93,341,594 | 89,192,252 | · | 68,395,343 | 68,371,139 | 64,222,178 | · | 49,633,104 | 45,565,991 | 42,725,863 | · | 42,525,855 | |
| Shares (Diluted) | 135,039,810 | 130,266,693 | · | 95,337,993 | 93,341,594 | 98,641,623 | · | 68,395,343 | 68,371,139 | 64,222,178 | · | 49,633,104 | 45,565,991 | 42,725,863 | · | 42,525,855 | |
| EBITDA | $-52M | $-43M | · | $-41M | $-43M | $-50M | · | $-48M | $-43M | $-39M | · | $-34M | $-33M | $-32M | · | $-25M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $433M | $466M | $150M | $186M | $222M | $260M | $165M | $207M | $229M | $263M | $220M | $248M | $148M | $117M | $143M | $173M | |
| Prepaid Expense | $42M | $44M | $42M | $56M | $54M | $45M | $36M | $26M | $36M | $31M | $41M | $36M | $45M | $50M | $48M | $45M | |
| Other Current Assets | $8M | $7M | $6M | $3M | $2M | $2M | $4M | $2M | $3M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | |
| Current Assets | $476M | $511M | $191M | $242M | $276M | $305M | $201M | $234M | $265M | $296M | $261M | $285M | $194M | $168M | $192M | $218M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $359.0K | $423.0K | $309.0K | $482.0K | $612.0K | $617.0K | $555.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Accum. Depreciation | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $395.0K | |
| Other Non-current Assets | $20M | $14M | $12M | $5M | $9M | $8M | $7M | $7M | $6M | $6M | $7M | $6M | $7M | $212.0K | $1M | $299.0K | |
| Total Assets | $505M | $532M | $210M | $256M | $294M | $319M | $214M | $247M | $279M | $309M | $276M | $299M | $210M | $173M | $197M | $225M | |
| Accounts Payable | $12M | $11M | $15M | $5M | $11M | $9M | $12M | $8M | $8M | $9M | $6M | $4M | $2M | $4M | $5M | $20M | |
| Current Liabilities | $367M | $154M | $248M | $197M | $31M | $30M | $34M | $26M | $22M | $19M | $20M | $15M | $13M | $11M | $16M | $30M | |
| Capital Leases | $2M | $779.0K | $1M | $2M | $2M | $259.0K | $303.0K | $459.0K | $799.0K | $1M | $2M | $2M | $3M | $412.0K | $418.0K | $425.0K | |
| Total Liabilities | $420M | $205M | $263M | $218M | $131M | $124M | $59M | $54M | $52M | $50M | $50M | $46M | $43M | $12M | $16M | $30M | |
| Long-term Debt | $51M | $50M | $32M | $31M | $31M | $31M | $30M | $30M | $29M | $29M | $29M | $28M | $28M | · | $0 | · | |
| Total Debt | $51M | $50M | · | $31M | $31M | $31M | · | $28M | · | · | · | · | · | · | · | · | |
| Common Stock | $1M | $1M | $973.0K | $973.0K | $946.0K | $938.0K | $702.0K | $699.0K | $699.0K | $699.0K | $635.0K | · | · | · | · | · | |
| Paid-in Capital | $1.08B | $1.07B | $784M | $781M | $767M | $763M | $705M | $700M | $695M | $690M | $622M | $617M | $496M | $464M | $459M | $455M | |
| Retained Earnings | $-985M | $-731M | $-823M | $-729M | $-591M | $-553M | $-535M | $-491M | $-453M | $-415M | $-380M | $-347M | $-314M | $-285M | $-261M | $-230M | |
| AOCI | $-15M | $-15M | $-15M | $-15M | $-15M | $-16M | $-16M | $-17M | $-17M | $-17M | $-17M | $-17M | $-17M | $-17M | $-17M | $-31M | |
| Stockholders' Equity | $85M | $327M | $-53M | $38M | $163M | $195M | $155M | $193M | $226M | $259M | $226M | $253M | $166M | $162M | $181M | $195M | |
| Liabilities + Equity | $505M | $532M | $210M | $256M | $294M | $319M | $214M | $247M | $279M | $309M | $276M | $299M | $210M | $173M | $197M | $225M | |
| Shares Outstanding | 135,722,306 | 134,923,295 | 96,085,785 | 96,002,044 | 93,586,348 | 92,848,326 | 68,552,215 | 68,409,068 | 68,387,469 | 68,342,534 | 61,943,471 | · | · | · | · | · |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $59.0K | $63.0K | $61.0K | · | $186.0K | $110.0K | $48.0K | $76.0K | $100.0K | |
| Stock-based Comp | $4M | $3M | $3M | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $4M | $4M | $5M | $4M | $3M | $4M | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $9M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-40M | $-48M | $-38M | $-35M | $-39M | $-46M | $-42M | $-22M | $-34M | $-21M | $-28M | $-17M | $-25M | $-28M | $-45M | $-19M | |
| CapEx | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $18.0K | $19.0K | $29.0K | $107.0K | $-5.0K | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-18.0K | $-17.0K | $-29.0K | $-107.0K | $5.0K | |
| Debt Issued | $0 | $19M | · | · | $0 | $0 | · | $0 | · | · | $0 | $0 | · | · | $0 | $0 | |
| Net Debt Issued | · | $19M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | $141M | $0 | $0 | $0 | $140M | $0 | $0 | $0 | $26M | $-41.0K | $117M | $27M | $1M | $440.0K | $0 | |
| Net Stock Activity | · | $141M | · | · | · | $140M | · | · | · | $26M | · | · | · | $1M | · | · | |
| Financing Cash Flow | $8M | $362M | $187.0K | $0 | $166.0K | $140M | $155.0K | $-53.0K | $210.0K | $64M | $41.0K | $117M | $56M | $1M | $639.0K | $-1.0K | |
| Net Change in Cash | $-33M | $316M | $-36M | $-36M | $-38M | $95M | $-42M | $-22M | $-34M | $43M | $-28M | $100M | $31M | $-26M | $-30M | $-34M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-21M | · | · | · | $-28M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-22M | · | · | · | · | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -63.6% | 21.4% | · | -54.8% | -13.4% | -5.7% | · | -14.1% | -15.6% | -14.6% | · | -12.8% | -12.6% | -10.9% | · | -16.4% | |
| ROE | -205.4% | 34.9% | · | -119.4% | -19.8% | -7.9% | · | -17.2% | -19.4% | -16.7% | · | -14.9% | -14.5% | -11.5% | · | -18.9% | |
| ROIC | -38.8% | -11.4% | · | -58.8% | -22.3% | -22.4% | · | -21.8% | -19.2% | -15.0% | · | -13.5% | -19.8% | -19.8% | · | -13.2% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 3.3 | · | 1.2 | 8.8 | 10.2 | · | 8.9 | 12.0 | 15.2 | · | 18.6 | 15.2 | 14.9 | · | 7.4 | |
| Quick Ratio | 1.2 | 3.0 | · | 0.9 | 7.1 | 8.7 | · | 7.9 | 10.4 | 13.5 | · | 16.2 | 11.6 | 10.4 | · | 5.9 | |
| Debt / Equity | 0.6 | 0.2 | · | 0.8 | 0.2 | 0.2 | · | 0.1 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | 0.2 | · | 0.5 | 0.1 | 0.1 | · | 0.1 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -35.1 | · | -31.5 | · | · | · | · |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.62 | $2.42 | · | $0.39 | $1.74 | $2.11 | · | $2.82 | $3.31 | $3.79 | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-0.37 | · | · | · | $-0.46 | · | · | · | $-0.32 | · | · | · | $-0.65 | · | · | |
| Cash / Share | $3.19 | $3.45 | · | $1.94 | $2.37 | $2.80 | · | $3.03 | $3.34 | $3.85 | · | · | · | · | · | · | |
| EPS (TTM) | $-4.61 | $-3.14 | · | $-2.72 | $-1.84 | $-1.99 | · | $617.25 | $617.14 | $-2.30 | · | $-621.97 | $-621.73 | $-2.23 | · | $-2.05 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-394M | $-179M | · | $-237M | $-138M | $-138M | · | $-144M | $-139M | $-129M | · | $-117M | $-102M | $-95M | · | $-86M | |
| Market Cap | $1.92B | $746M | · | $550M | $262M | $266M | · | $431M | $413M | $569M | · | · | · | · | · | · | |
| Enterprise Value | $1.54B | $331M | · | $395M | $71M | $36M | · | $252M | · | · | · | · | · | · | · | · | |
| P/E | -3.1 | -1.8 | · | -2.1 | -1.5 | -1.4 | · | 0.0 | 0.0 | -3.6 | · | -0.0 | -0.0 | -4.5 | · | -5.2 | |
| P/B | 22.7 | 2.3 | · | 14.6 | 1.6 | 1.4 | · | 2.2 | 1.8 | 2.2 | · | · | · | · | · | · | |
| P / Tangible Book | 22.7 | 2.3 | · | 14.6 | 1.6 | 1.4 | · | 2.2 | 1.8 | 2.2 | · | · | · | · | · | · | |
| P / Cash Flow | · | -15.6 | · | · | · | -5.8 | · | · | · | -27.3 | · | · | · | · | · | · | |
| Earnings Yield | -32.6% | -56.8% | · | -47.5% | -65.7% | -69.6% | · | 9797.6% | 10217.5% | -27.6% | · | -8405.0% | -7508.8% | -22.5% | · | -19.1% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 净收入 | $-288M | $-155M | $-118M | $-92M | $-72M |
| 稀释后每股收益 (EPS) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | -0.6 | 0.2 | · | · | · |
| 流动比率 | 0.8 | 5.9 | 13.3 | 12.3 | 19.5 |
| 速动比率 | 0.6 | 4.9 | 11.2 | 9.2 | 18.1 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | · | $-119M | $-97M | $-106M | $-68M |
机构持有人 (13F) 248 家申报者 · $1.4B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
248
持有价值
$1.4B
新仓位
65
已退出持仓
30
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 65 (+5 与上一季度对比) | 30 (+7 与上一季度对比) | 78 (+4 与上一季度对比) | 54 (+25 与上一季度对比) | -1.1M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| Deep Track Capital, LP | $172085168 | 12161496 | 12.70% | 股份 |
| RTW INVESTMENTS, LP | $151418782 | 10700974 | 11.18% | 股份 |
| BIT Capital GmbH | $89835478 | 6348797 | 6.63% | 股份 |
| TANG CAPITAL MANAGEMENT LLC | $70750000 | 5000000 | 5.22% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $63257363 | 4470485 | 4.67% | 股份 |
| MARSHALL WACE, LLP | $61250852 | 4328682 | 4.52% | 股份 |
| ARK Investment Management LLC | $48845310 | 3451965 | 3.61% | 股份 |
| Point72 Asset Management, L.P. | $37085424 | 2620878 | 2.74% | 股份 |
| Logos Global Management LP | $31837500 | 2250000 | 2.35% | 股份 |
| Eagle Health Investments LP | $29155042 | 2060427 | 2.15% | 股份 |
| BANK OF AMERICA CORP /DE/ | $28573774 | 2019348 | 2.11% | 股份 |
| DAFNA Capital Management LLC | $28469121 | 2011952 | 2.10% | 股份 |
| Caption Management, LLC | $27544390 | 1946600 | 2.03% | 买入期权 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $26855285 | 1897900 | 1.98% | 买入期权 |
| NEXTBio Capital Management LP | $25126990 | 1775759 | 1.85% | 股份 |
| UBS Group AG | $20976951 | 1482470 | 1.55% | 股份 |
| Aisling Capital Management LP | $20267554 | 1432336 | 1.50% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $20261229 | 1431889 | 1.50% | 股份 |
| Candriam S.C.A. | $18013686 | 1274278 | 1.33% | 股份 |
| Woodline Partners LP | $15366957 | 1086004 | 1.13% | 股份 |
| CITADEL ADVISORS LLC | $14219052 | 1004880 | 1.05% | 股份 |
| Jefferies Financial Group Inc. | $14070661 | 994393 | 1.04% | 股份 |
| BlackRock, Inc. | $13094283 | 925391 | 0.97% | 股份 |
| Trexquant Investment LP | $12171236 | 860158 | 0.90% | 股份 |
| Kalehua Capital Management LLC | $11598642 | 819692 | 0.86% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $10909466 | 770987 | 0.81% | 股份 |
| Caption Management, LLC | $10699041 | 756116 | 0.79% | 股份 |
| Eversept Partners, LP | $9520474 | 672825 | 0.70% | 股份 |
| MORGAN STANLEY | $8417922 | 594906 | 0.62% | 股份 |
| Propel Bio Management, LLC | $8109167 | 573086 | 0.60% | 股份 |
| Creek Drive Management Group LLC | $8093800 | 572000 | 0.60% | 股份 |
| Occam Crest Management LP | $7739000 | 710000 | 0.57% | 股份 |
| CITADEL ADVISORS LLC | $7567420 | 534800 | 0.56% | 买入期权 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7140090 | 504600 | 0.53% | 卖出期权 |
| SILVERARC CAPITAL MANAGEMENT, LLC | $7122855 | 503382 | 0.53% | 股份 |
| JANE STREET GROUP, LLC | $7102310 | 501930 | 0.52% | 股份 |
| Qube Research & Technologies Ltd | $7070415 | 499676 | 0.52% | 股份 |
| Walleye Capital LLC | $6893385 | 487165 | 0.51% | 股份 |
| Ensign Peak Advisors, Inc | $6716340 | 474653 | 0.50% | 股份 |
| Blue Owl Capital Holdings LP | $6367500 | 450000 | 0.47% | 股份 |
| AdvisorShares Investments LLC | $5962060 | 421347 | 0.44% | 股份 |
| TWO SIGMA ADVISERS, LP | $5909850 | 856500 | 0.44% | 股份 |
| GOLDMAN SACHS GROUP INC | $5540956 | 391587 | 0.41% | 股份 |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | $5438567 | 384351 | 0.40% | 股份 |
| HighVista Strategies LLC | $5251349 | 371120 | 0.39% | 股份 |
| Legal & General Group Plc | $4700154 | 332206 | 0.35% | 股份 |
| Sumitomo Mitsui Trust Group, Inc. | $4573407 | 323209 | 0.34% | 股份 |
| Amova Asset Management Americas, Inc. | $4517334 | 319472 | 0.33% | 股份 |
| Squadron Capital Management LLC | $4315750 | 305000 | 0.32% | 买入期权 |
| Affinity Asset Advisors, LLC | $4261739 | 301183 | 0.31% | 股份 |
激进投资者及 5%+ 股东 1 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| AtaiBeckley Inc. | 2026年2月17日 | 4.96% | 修订 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 19 位内幕人士 · 6 位高管 · 10 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Kabir Nath | Chief Executive Officer | 2026年8月3日 F | 361028 | 0 | 0 | $0 |
| Teri Loxam | Chief Financial Officer | 2026年3月26日 A | 152002 | 0 | 0 | $0 |
| Mary-Rose Hughes | Interim CFO | 2024年2月1日 A | · | 0 | 0 | $0 |
| Michael Falvey | Chief Financial Officer | 2023年2月2日 A | 22500 | 0 | 0 | $0 |
| Guy Goodwin | Chief Medical Officer | 2026年3月26日 A | 8000 | 0 | 0 | $0 |
| Matthew A Owens | General Counsel & CLO | 2024年2月1日 A | 43340 | 0 | 0 | $0 |
| Robert Mcquade | 董事 | 2026年5月27日 A | · | 0 | 0 | $0 |
| Kathleen Tregoning | 董事 | 2026年5月27日 A | · | 0 | 0 | $0 |
| Daphne Karydas | 董事 | 2026年5月27日 A | · | 0 | 0 | $0 |
| Justin D. Gover | 董事 | 2026年5月27日 A | · | 0 | 0 | $0 |
| David Y Norton | 董事 | 2026年5月27日 A | 20356 | 0 | 0 | $0 |
| Wayne Joseph Riley | 董事 | 2026年5月27日 A | · | 0 | 0 | $0 |
| Thomas Lonngren | 董事 | 2025年6月12日 A | · | 0 | 0 | $0 |
| Annalisa Jenkins | 董事 | 2025年6月12日 A | 19480 | 0 | 0 | $0 |
| Linda Mcgoldrick | 董事 | 2025年6月12日 A | · | 0 | 0 | $0 |
| Ekaterina Malievskaia | 10% 所有者 | 2024年10月24日 S | 3155122 | 0 | 0 | $0 |
| George Jay Goldsmith | 10% 所有者 | 2024年10月24日 S | 3152848 | 0 | 0 | $0 |
| Gino Santini | · | 2026年5月27日 A | · | 0 | 0 | $0 |
| Jeffrey M Jonas | · | 2026年5月27日 A | · | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 6 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| ARKG · ARK ETF Trust | 3.25% | 4463875 NS | 2026年7月31日 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 0.93% | 56358 NS | 2026年7月31日 | N-PORT |
| BBC · ETFis Series Trust I | 0.63% | 25731 NS | 2026年7月31日 | N-PORT |
| ESIM · Strategy Shares | 0.13% | 2020 NS | 2026年7月31日 | N-PORT |
| IBB · iShares Trust | 0.11% | 831209 SH | 2026年9月11日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.11% | 9493 SH | 2026年10月2日 | 每日 |
CMPS 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 24 位分析师
买入
中位数目标
$21.00
+76.5%
8 33.3%
强烈买入
14 58.3%
买入
2 8.3%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
16 位分析师 · 2026-10-04平均目标 $23.75 +99.6%
← 低于所有目标
当前价格 $11.90
最低$13.00
平均值$23.75
最高$65.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 5, 2026 申报